Universal Beteiligungs und Servicegesellschaft mbH Invests $38.82 Million in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 93,890 shares of the company's stock, valued at approximately $38,818,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.12% of IDEXX Laboratories at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of IDXX. United Capital Financial Advisors LLC lifted its position in shares of IDEXX Laboratories by 0.9% during the fourth quarter. United Capital Financial Advisors LLC now owns 2,446 shares of the company's stock worth $1,011,000 after purchasing an additional 22 shares in the last quarter. Gabelli Funds LLC boosted its holdings in IDEXX Laboratories by 5.3% during the fourth quarter. Gabelli Funds LLC now owns 500 shares of the company's stock worth $207,000 after purchasing an additional 25 shares during the last quarter. Perigon Wealth Management LLC boosted its holdings in IDEXX Laboratories by 1.8% during the fourth quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock worth $632,000 after purchasing an additional 26 shares during the last quarter. Summit Trail Advisors LLC lifted its stake in IDEXX Laboratories by 3.3% in the fourth quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock valued at $335,000 after acquiring an additional 26 shares during the last quarter. Finally, Forum Financial Management LP raised its position in shares of IDEXX Laboratories by 4.9% in the fourth quarter. Forum Financial Management LP now owns 621 shares of the company's stock valued at $257,000 after purchasing an additional 29 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

IDXX has been the subject of several analyst reports. Stifel Nicolaus boosted their target price on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a research report on Monday, May 19th. Wall Street Zen downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Friday. Piper Sandler upped their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Bank of America increased their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Finally, Barclays upped their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, IDEXX Laboratories has a consensus rating of "Moderate Buy" and a consensus price target of $536.00.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the business's stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the transaction, the director now owns 1,801 shares of the company's stock, valued at approximately $922,724.34. The trade was a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Stock Down 0.6%

IDXX stock traded down $3.03 during trading on Friday, reaching $512.52. 1,221,827 shares of the company traded hands, compared to its average volume of 652,599. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $530.60. The business has a 50 day simple moving average of $449.80 and a 200 day simple moving average of $437.41. The company has a market capitalization of $41.22 billion, a price-to-earnings ratio of 48.03, a price-to-earnings-growth ratio of 3.41 and a beta of 1.52. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The business had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. During the same quarter last year, the company earned $2.71 earnings per share. The company's quarterly revenue was up 3.6% on a year-over-year basis. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.